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Mechanically induced ATP release from human air-
way epithelial cells regulates mucociliary clearance
through cell surface nucleotide receptors. Ectoenzymes
detected on these cells were recently shown to termi-
nate ATP-mediated responses by sequential dephospho-
rylation of extracellular ATP into ADP, AMP, and aden-
osine. We now demonstrate that an ecto-adenylate
kinase (ecto-AK) contributes to the metabolism of ade-
nine nucleotides on human airway epithelial surfaces
by the reversible reaction: ATP  AMP u 2ADP. This
phosphotransferase exhibited a bilateral distribution
on polarized primary cultures of human bronchial epi-
thelial cells with a 4-fold higher activity on the mucosal
surface. Ecto-AK presented an absolute requirement for
magnesium and adenine-based nucleotides. UMP, GMP,
and CMP could not substitute for AMP as -phosphate
acceptor, and UDP could not replace ADP. Apparent Km
and Vmax values were 23  5 M and 1.1  0.1
nmolmin1cm2 for ATP and 43  6 M and 0.5  0.1
nmolmin1cm2 for ADP. Ecto-AK accounted for 20%
of [-32P]ATP dephosphorylation, and the impermeant
AK inhibitor, diadenosine pentaphosphate, reduced
ADPase activity by more than 70% on both epithelial
surfaces. Time course experiments on ATP metabolism
demonstrated that ecto-AK significantly prolongs effec-
tive ATP and ADP concentrations on airway epithelial
surfaces for P2 receptor signaling and reduces by 6-fold
adenosine production. Our data suggest a role for this
nucleotide entrapment cycle in the propagation of pu-
rine-mediated mucociliary clearance on human airway
epithelial surfaces.
Mucociliary clearance (MCC)1 represents the first line of
defense against lung infection. Inhaled bacteria are trapped
within a mucus blanket covering the epithelium and mechan-
ically cleared by coordinated cilia beating activity (for a review,
see Ref. 1). Extracellular nucleotides are well recognized as
regulators of the epithelial functions supporting MCC, includ-
ing mucus secretion, cilia beat frequency (CBF), and ion chan-
nel activities involved in the maintenance of epithelial surface
liquid volume (for a review, see Ref. 2). Nucleotides are re-
leased by the epithelium under basal conditions (3, 4) and in
response to membrane stretch (5, 6), shear stress (7, 8), and
hypo-osmotic cell swelling (9–12). On the mucosal surface, they
interact with two members of the G-protein-coupled P2Y recep-
tor (P2YR) family: P2Y2 (13) and P2Y6 (14). P2Y2 receptors are
equally activated by ATP and UTP, but not by ADP or UDP,
whereas P2Y6 receptors are potently activated by UDP and
weakly activated by ADP. The serosal epithelial surface ex-
presses P2Y2 (15) and P2Y1 (ADP  ATP  UTP) (6) receptors.
Taylor et al. (17) demonstrated that human airway epithelial
cultures also express members of the ionotropic P2X receptor
(P2XR) family: P2X4 and P2X5. Patch clamp and Ussing cham-
ber experiments indicated that ATP-induced Ca2 entry
through these channels stimulates luminal Cl secretion. In
rabbit trachea, epithelial P2XRs contribute to ATP-mediated
increase in CBF via Ca2 influx (18).
Over the last decade, several studies have demonstrated the
role of cell surface nucleotide metabolism in the regulation of
MCC-related epithelial functions (9, 10, 19, 22). ATP and UTP
elicited large transient increases in CBF on human nasal ex-
plants (19). However, ATP also produced a post-peak sustained
increase in CBF that was prevented by the nonspecific adeno-
sine receptor antagonist, 8-p-sulfophenyltheophylline. Hypoto-
nicity-induced cell swelling triggered ATP release and activa-
tion of volume-sensitive Cl channels by a mechanism that
required cell surface conversion of ATP into adenosine (10). In
a human bronchial cell line lacking P2Y2 receptors (Calu-3
(23)), the basal ion channel activity of the cystic fibrosis trans-
membrane regulator (CFTR) was inhibited by 8-p-sulfophenyl-
theophylline and by AMPCP (22), an inhibitor of the cell sur-
face conversion of AMP into adenosine (for a review, see Ref.
24). Incidentally, adenosine has been shown to trigger MCC-
related epithelial responses, including CBF (19, 25) and ion
transport (26–28).
We reported that human nasal and bronchial epithelial sur-
faces express metabolic enzymes that sequentially dephospho-
rylate ATP into ADP, AMP, and adenosine and UTP into UDP,
UMP, and uridine (29–31). Lazarowski et al. (32) proposed that
extracellular nucleotide metabolism in human airways also
involves transphosphorylating enzymes. They identified a nu-
cleoside diphosphate kinase (NDPK) activity on the mucosal
surface of human nasal epithelial cells. Classically described as
ubiquitous intracellular enzymes, NDPKs catalyze the transfer
of -phosphate groups between nucleoside di- and triphos-
phates by the reversible reaction: NTP  NDPu NDP  NTP
(for a review, see Ref. 33). Transphosphorylation events taking
place in most intracellular compartments combine the activi-
ties of NDPKs and adenylate kinases (AKs; ATP:AMP-phos-
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photransferases). In contrast to the broad substrate specificity
of NDPKs, AKs transfer phosphate groups between adenine-
based nucleotides by the reaction: MgATP  AMPuMgADP 
ADP (for a review, see Ref. 34). Cell surface AK (ecto-AK)
activity was recently detected on Sartorius frog muscles (35,
36), rat brain synaptosomes (37), human umbilical vein endo-
thelial cells (38, 39), and human nasal epithelial cells (40).
However, the physiological role of cell surface adenine nucleo-
tide transphosphorylation has not been explored.
In the present study, we describe the biochemical and kinetic
properties, as well as the polarity, of ecto-AK expressed at the
surface of human bronchial epithelia. We measured the impact
of ecto-AK on the availability of adenine nucleotides for P2
(ATP and ADP) and P1 (adenosine) receptors regulating MCC.
We tested the hypothesis that ecto-AK could extend the dura-
tion of locally released ATP to promote airway clearance of
noxious agents. Biochemical assays were performed on polar-
ized primary cultures of bronchial epithelial cells from normal
donors and patients diagnosed with cystic fibrosis (CF), an
inherited obstructive lung disease characterized by impaired
MCC, chronic infection, and inflammation (for a review, see
Ref. 41). This study provides evidence that ecto-AK plays a
major role in the prolongation of P1 and P2 receptor-mediated
MCC functions on human airway epithelial surfaces.
EXPERIMENTAL PROCEDURES
Cell Culture—Well differentiated primary cultures of human bron-
chial epithelial cells were grown as described previously (42). In brief,
the cells were isolated from freshly excised main stem bronchi by
protein digestion (43) and plated on porous Transwell Col filters (well
diameter, 12 mm; pore size, 0.45 M) in air-liquid interface medium
(50:50 mixture of LHC basal and Dulbecco’s modified Eagle’s medium-
high glucose, 0.5 ng/ml epidermal growth factor, 50 nM retinoic acid, 0.5
mg/ml bovine serum albumin, 0.8% bovine pituitary extract, 50
units/ml penicillin, and 50 g/l streptomycin) (44). Once they reached
confluence, the cultures were maintained in air-liquid interface with
medium added only to the serosal compartment. After 4 weeks, the
cultures were composed of columnar ciliated cells (90%) and secretory
cells covering a layer of basal-like cells (45). Enzyme assays were
conducted on cultures with transepithelial electrical resistance  300
ohmscm2. Lactate dehydrogenase activity was employed as a test of
cellular integrity.
Ectonucleotidase Assays—Primary cultures of human bronchial epi-
thelial cells were rinsed three times with Krebs-Ringer buffer (KRB):
140 mM Na, 120 mM Cl, 5.2 mM K, 25 mM HCO3
, 2.4 mM HPO4
, 1.6
mM Ca2, 1.6 mM Mg2, 5.2 mM glucose, and 25 mM HEPES (pH 7.4),
and preincubated in KRB (350 l mucosal/serosal) for 30 min at 37 °C
(5% CO2/95% O2). All reactions were initiated by the addition of the
substrate(s), dissolved in 35 l of KRB, to the mucosal or serosal bath,
and stopped by transferring 10-l aliquots to tubes containing 300 l of
ice-cold water. The samples were boiled for 5 min, filtered, and analyzed
by reversed-phase paired-ion HPLC. ATPase activity was measured
with [3H]ATP (0.5 Ci) or [-32P]ATP (0.1 Ci) as substrates. ADPase
and UDPase activities were assayed with [3H]ADP (0.5 Ci) and
[3H]UDP (0.5 Ci), respectively. The forward ecto-AK reaction (ATP 
AMP 3 2ADP) was initiated with equal concentrations of [-32P]ATP
(0.1 Ci) and AMP mixed previously and then quantified by the rate of
[-32P]ADP production. The reverse ecto-AK reaction (2ADP 3 ATP 
AMP) was measured by the rate of [3H]ATP production from [3H]ADP
(0.5 Ci).
Synthesis of [3H]ADP and [3H]UDP—Tritiated ADP and UDP were
obtained from their respective nucleoside triphosphates by hexokinase
reaction, as described previously (46). In brief, 50 Ci of either [3H]ATP
or [3H]UTP (40–50 Ci/mmol) were incubated with 10 units/ml hexoki-
nase (30 min; 37 °C) in 0.2 ml of KRB. The samples were boiled for 3
min to eliminate hexokinase activity, and full conversion into [3H]ADP
or [3H]UDP was confirmed by HPLC.
Enzyme Release Assays—Mucosal epithelial surfaces were rinsed
three times with KRB and incubated in KRB (350 l of mucosal/serosal)
during 90 min at 37 °C (5% CO2/95% O2). The conditioned buffer was
collected and centrifuged at 14,000  g (4 °C; 20 min) to remove de-
tached cells, debris, and large organelles. The supernatant was trans-
ferred to tubes containing 1 mM [-32P]ATP (0.1 Ci) or 1 mM
[-32P]ATP (0.1 Ci)  1 mM AMP in 35 l KRB for assessment of
ATPase and ecto-AK activities in a shaker bath (37 °C). These values
were compared with enzyme activities measured the following day on
the same cultures to ascertain the contribution of released enzymes to
total epithelial surface activity.
Kinetic Properties of Human Airway Ecto-AK—We established the
kinetic properties of the forward and reverse ecto-AK reactions for ATP
and ADP, respectively. For the forward reaction, the assays were initi-
ated with 1 mM AMP  0.001–1 mM [-32P]ATP (0.1 Ci), and reaction
rates were calculated from [-32P]ADP production. For the reverse
reaction, the assays were initiated with 0.001–1 mM [3H]ADP (0.5 Ci),
and reaction rates were calculated from [3H]ATP production. All exper-
iments were conducted on the mucosal surface of human bronchial
epithelial cultures, as described above for enzyme assays. Samples were
collected after incubation periods that limited substrate hydrolysis to
10% and were analyzed by HPLC. Michaelis-Menten constants (Km)
and maximal velocities (Vmax) were obtained from the slope and the
ordinate of Woolf-Augustinson Hoftsee transformations, respectively.
Catalytic efficiency (Cateff) was calculated from the velocity (Vo) at Km
divided by Km (47).
HPLC Separation of Nucleotides—The separation system consisted
of a Dinamax C-18 column and a mobile phase developed with buffer A
(10 mM KH2PO4 and 8 mM tetrabutyl ammonium hydrogen sulfate
(TBASH), pH 5.3) from 0 to 10 min, buffer B (100 mM KH2PO4, 8 mM
TBASH, and 10% MeOH, pH 5.3) from 10 to 20 min and buffer A from
20 to 30 min. Absorbance was monitored at 254 nm with an on-line
Model 490 multiwavelength detector (Shimadzu Scientific Instruments,
Columbia, MD), and radioactivity was determined on-line with a Flo-
One Radiomatic  detector (Packard, Canberra, Australia), as described
previously (48).
Materials—All 5-nucleotides and adenosine were purchased from
Roche Molecular Biochemicals. KH2PO4, TBASH, and HEPES were
obtained from Sigma. HPLC-grade water was bought from Fisher Sci-
entific. Cell culture media, bovine serum albumin, bovine pituitary
extract, epidermal growth factor, gentamicin, penicillin, retinoic acid,
and streptomycin were bought from Invitrogen. [2,83H]ATP (40–50
Ci/mmol), [2,83H]UTP (40–50 Ci/mmol), and [-32P]ATP (3000 Ci/
mmol) were obtained from Amersham Biosciences. Salts and solvents
were of analytical grade.
Data Analysis—All enzyme assays were performed on primary cul-
tures of human bronchial epithelial cells obtained from at least five
different donors or CF patients. Rates of dephosphorylation were cal-
culated from the initial linear rate of substrate decay monitored by
HPLC and presented as nmolmin1cm2. Forward and reverse
ecto-AK activities were calculated from initial linear rates of accumu-
lation of the phosphorylated product. Values were expressed as
means  S.E. Unpaired Student’s t tests were used to assess the
significance between measurements performed on different cultures.
Paired T tests were used for comparisons between mucosal and serosal
surfaces of the same culture or between conditioned buffer and the
corresponding epithelial surface. All linear regressions, curve, fits and
data transformations were performed with the PC computer programs
Origin and Sigma plot.
RESULTS
Detection of Ectonucleotidase and Ecto-AK Activities on
Airway Epithelia—Polarized bronchial epithelial cultures
were assayed for nucleotide metabolism. Fig. 1A presents
typical HPLC traces for samples collected 0, 2, and 5 min
after the addition of 0.1 mM [3H]ATP to the mucosal surface.
The nucleotide was converted into less phosphorylated com-
pounds ([3H]ADP, [3H]AMP, [3H]adenosine) and [3H]inosine.
Time course analysis showed that the disappearance of
[3H]ATP occurred during the accumulation of [3H]ADP and
[3H]AMP (Fig. 1B). [3H]Adenosine concentration increased
over the first 40 min and accounted for 50% of all radioactive
species by the end of the experiment. In contrast, reactions
initiated with 0.1 mM [3H]ADP indicated that adenine nucle-
otide metabolism involves other activities besides dephospho-
rylation. As observed with [3H]ATP, [3H]ADP was converted
into less phosphorylated compounds ([3H]AMP, [3H]ade-
nosine) and [3H]inosine (Fig. 1C). The HPLC traces also
revealed the presence of [3H]ATP, suggesting that [3H]ADP
was phosphorylated. Time course analysis showed transient
accumulation of [3H]AMP and [3H]ATP during the first 30
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min, whereas adenosine and inosine concentrations in-
creased during the entire incubation period (Fig. 1D). These
results support a complex interplay between dephosphorylat-
ing and phosphorylating activities on human airway epithe-
lial surfaces.
We explored the possibility that an ecto-AK was responsible
for the phosphorylation of ADP into ATP at the surface of
human bronchial epithelial cells. By definition, an AK supports
the reversible reaction: ATP  AMPu 2ADP (for a review, see
Ref. 34). We already demonstrated that these epithelial cul-
tures support the reverse reaction (2ADP3 ATP  AMP; Fig.
1, C and D). In the following experiments, we investigated the
forward AK reaction (ATP  AMP 3 2ADP). Fig. 2A shows
typical HPLC traces obtained from buffer samples collected 0,
2, and 5 min after the addition of 0.1 mM [-32P]ATP to the
mucosal surface. The dephosphorylation of [-32P]ATP was de-
tected by the accumulation of inorganic phosphate ([32P]Pi).
Reactions initiated with 0.1 mM [-32P]ATP  0.1 mM AMP
produced an additional radioactive compound that co-migrated
with ADP standards (Fig. 2B), suggesting that the -phosphate
group of [-32P]ATP was transferred to AMP to produce
[-32P]ADP. These experiments demonstrated that human air-
way epithelial surfaces exhibit both forward and reverse AK
activities.
Cell-associated Ecto-AK and ATPase Activities—The muco-
sal surface of human bronchial epithelial cultures and condi-
tioned KRB were assayed for ATPase and AK activities with 1
mM [-32P]ATP and 1 mM [-32P]ATP  1 mM AMP, respectively
(see “Experimental Procedures”). Similar levels of ATPase and
AK activities were detected in the conditioned KRB (Fig. 3A).
On the epithelial surface, the rate of [-32P]ATP dephosphoryl-
ation by ATPase activity was 5-fold higher than the rate of
AMP phosphorylation by AK activity (Fig. 3B). Importantly,
released ATPase and AK activities represented 3  1% and
11  2% of total surface activity, respectively. The cell surface
enzymes, remaining on the bronchial culture after the condi-
tioned KRB was collected, were not eluted by subsequent
washes (five rapid changes in KRB). These experiments indi-
cate that the ectoenzymes responsible for the interconversion of
phosphate groups between extracellular nucleotides were pre-
FIG. 2. Detection of ecto-AK activity on human bronchial epi-
thelial cells. The epithelial cultures were incubated with KRB (pH 7.4;
0.35 ml mucosal/serosal) containing mucosal 0.1 mM [-32P]ATP (0.1
Ci) (A) or 0.1 mM [-32P]ATP (0.1 Ci)  0.1 mM AMP (B). Buffer
samples (10 l) collected over 10 min were analyzed by HPLC. HPLC
traces are presented for buffer samples collected after 0, 2, and 5 min.
As shown in A, [-32P]ATP dephosphorylation was detected by
[32P]inorganic phosphate ([32P]Pi) release. As shown in B, addition of
0.1 mM [-32P]ATP  0.1 mM AMP generated [32P]Pi by dephosphoryl-
ation and [-32P]ADP by ecto-AK phosphorylation. HPLC traces repre-
sent typical results from six independent experiments.
FIG. 3. Contribution of released enzymes to cell surface
ecto-AK and ATPases. A, enzyme activities released from the mucosal
surface. KRB was conditioned by a 90-min exposure to the mucosal
surface. B, cell-associated enzyme activities. The mucosal surface was
assayed for total enzyme activities. ATPase (filled bars) and ecto-AK
(open bars) activities were assayed in KRB (pH 7.4) with 0.1 mM
[-32P]ATP (0.1 Ci) and 0.1 mM [-32P]ATP (0.1 Ci)  0.1 mM AMP,
respectively. Buffer samples (10 l) collected over 10 min were analyzed
by HPLC. Released enzyme activities accounted for 15% of total
epithelial surface activity. Values represent mean  S.E. of five inde-
pendent experiments (*, p  0.01).
FIG. 1. ATP and ADP metabolism at the surface of human
bronchial epithelial cells. The epithelial cultures were incubated
with KRB (pH 7.4; 0.35 ml mucosal/serosal) containing mucosal 0.1 mM
[3H]ATP (0.5 Ci) (A and B) or 0.1 mM [3H]ADP (0.5 Ci) (C and D).
Buffer samples collected over 60 min and analyzed by HPLC revealed
[3H]ATP (A) and [3H]ADP (C) dephosphorylation, as well as phospho-
rylation of [3H]ADP into [3H]ATP (C and D). Time course analyses
indicated significant differences in the patterns of [3H]ATP (B) and
[3H]ADP (D) metabolism on bronchial epithelial cells: [3H]ATP (),
[3H]ADP (f), [3H]AMP (Œ), [3H]adenosine (), [3H]inosine (). HPLC
traces represent typical results obtained from six independent experi-
ments. Metabolic patterns represent mean results from all experiments
(S.E.  10% of the mean).
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dominantly associated to the epithelial surface of human bron-
chial epithelial cells.
Cation Dependence and Substrate Specificity of Ecto-AK—
Human airway ecto-AK exhibited an absolute requirement for
divalent cations and adenine nucleotides, as reported for intra-
cellular AKs (34, 49). Enzyme assays were conducted on the
mucosal surface of human bronchial epithelial cultures with
0.1 mM [-32P]ATP  0.1 mM AMP. The kinase activity was not
detected in Mg2-free KRB containing millimolar Ca2 (Fig.
4A). The rate of AMP phosphorylation was proportional to the
Mg2 concentration. Fig. 4B shows that UMP, GMP, and CMP
could not substitute for AMP as phosphate acceptor for the
forward ecto-AK reaction. In addition, UDP could not substi-
tute for ADP as phosphate donor or acceptor for the reverse
ecto-AK reaction (Fig. 4, C and D). Fig. 4C presents typical
HPLC traces for buffer samples collected 0, 5, and 10 min after
the addition of 0.1 mM [3H]UDP to the mucosal surface. The
nucleotide was gradually dephosphorylated into [3H]UMP and
[3H]uridine but was not phosphorylated into [3H]UTP (Fig.
4D). Taken together, these results indicate the presence of a
Mg2-dependent ecto-AK activity specific for adenine nucleo-
tides at the surface of human bronchial epithelial cells.
Kinetic Properties of Human Airway Ecto-AK—Experiments
were designed to compare the kinetic properties of the forward
and reverse ecto-AK reactions on the mucosal surface of human
bronchial epithelial cells. The forward reaction was measured
with 1 mM AMP  0.001–1 mM [-32P]ATP. Fig. 5A shows that
the rate of [-32P]ADP production increased with substrate
concentration and saturated with 0.6 mM [-32P]ATP. The re-
verse reaction was measured with 0.001–3 mM [3H]ADP. The
production of [3H]ATP saturated at a higher substrate concen-
tration than the forward reaction (Fig. 5B; p  0.05). Woolf-
Augustinson Hoftsee analysis indicated that the Km for
[-32P]ATP was 2-fold lower than for [3H]ADP with correspond-
ing values of 23  5 M and 43  6 M, respectively (Fig. 5, A
and B, insets; p  0.05). The Vmax of the forward reaction was
2-fold higher than for the reverse reaction with values of 1.1 
0.1 nmolmin1cm2 and 0.5  0.1 nmolmin1cm2, respec-
tively (Fig. 5, A and B, insets; p  0.05). Calculated Cateff were
0.025  0.005 min1 and 0.014  0.002 min1 for [-32P]ADP
and [3H]ATP production, respectively (p  0.05).
Polarity and Directionality of Ecto-AK on Airway Epithelial
Surfaces—Nucleotide transphosphorylation was detected on
both mucosal and serosal surfaces of human bronchial epithe-
lial cultures (Table I). Enzyme assays, performed with satura-
ble substrate concentrations, indicated that forward and re-
verse activities were 4-fold higher on the mucosal surface
(Table I, reactions 1–2; p  0.01). These experiments also
showed that ecto-AK favored AMP phosphorylation by 3-fold
over [3H]ADP phosphorylation on both epithelial surfaces (p 
0.01). These results were in agreement with the higher affinity
of the enzyme for ATP over ADP (Fig. 5, A and B). The direc-
tionality of the reversible ecto-AK reaction suggested that the
enzyme could partially circumvent the loss of high energy
phosphate groups resulting from dephosphorylation of AMP
into adenosine.
Contribution of Ecto-AK to ADP Metabolism—We evaluated
the contribution of ecto-AK to the metabolism of ADP on hu-
man bronchial epithelial surfaces with the non-permeant AK
inhibitor, diadenosine pentaphosphate (Ap5A (37)). This dinu-
FIG. 4. Biochemical properties of ecto-AK on human bronchial
epithelial cells. A, absolute requirement for Mg2. Epithelial cultures
were incubated in KRB (pH 7.4) containing 0.1 mM [-32P]ATP (0.1 Ci)
 0.1 mM AMP in the mucosal bath. Buffer samples (10 l) collected
over 10 min were analyzed by HPLC. KRB contained 1.5 mM Ca2  0,
0.5, or 1.5 mM Mg2. B–D, ecto-AK specificity for adenine-based nucle-
otides. As shown in B, mucosal 0.1 mM [-32P]ATP (0.1 Ci) phospho-
rylated 0.1 mM AMP but not UMP, CMP, or GMP. C, HPLC traces for
the metabolism of mucosal 0.1 mM [3H]UDP (0.1 Ci). As shown in D,
time course assays showed that [3H]UDP (f) was dephosphorylated
into [3H]UMP (Œ) and [3H]uridine () but not phosphorylated into
[3H]UTP. Bar diagrams show means  S.E. of 6–8 independent exper-
iments (*, p  0.05). HPLC traces represent typical results and meta-
bolic patterns mean results (S.E.  10% of the mean) from all
experiments.
FIG. 5. Kinetic properties of human bronchial ecto-AK. A, cat-
alytic properties of the forward reaction, initiated with 1 mM AMP 
0.001–1 mM [-32P]ATP (0.1 Ci). [-32P]ADP production saturated
with 0.6 mM [-32P]ATP. Inset, Woolf-Augustinson Hoftsee transforma-
tion fitted to one regression (r 	 0.96–0.99) with Km, Vmax, and catalytic
efficiencies of 23  5 M, 1.1  0.1 nmolmin1cm2, and 0.025  0.005
min1, respectively. B, catalytic properties of the reverse reaction,
initiated with 0.001–3 mM [3H]ADP (0.5 Ci). Inset, Woolf-Augustinson
Hoftsee transformation fitted to one regression (r 	 0.97–0.99) with Km,
Vmax, and catalytic efficiencies of 43  6 M, 0.5  0.1 nmolmin
1cm2,
and 0.014  0.002 min1, respectively. Samples were collected after
incubation periods that limited substrate hydrolysis to 10% and then
analyzed by HPLC. Values represent mean  S.E. of five independent
experiments.
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cleotide was shown to act as competitive inhibitor for the for-
ward AK reaction (ATP  AMP3 2ADP) and non-competitive
inhibitor for the reverse AK reaction [2ADP 3 ATP  AMP]
(50). We tested the impact of Ap5A on the phosphorylation of
ADP by human bronchial ecto-AK. Dose-response curves were
constructed on mucosal and serosal surfaces with 2 mM
[3H]ADP and a range (0–0.5 mM) of Ap5A concentrations. Fig.
6A shows that [3H]ATP production was inhibited in a dose-de-
pendent manner and completely abolished by 0.5 mM Ap5A. In
the absence of ecto-AK activity, the pattern of [3H]ADP metab-
olism (Fig. 6B) closely resembled the pattern of [3H]UDP me-
tabolism (Fig. 4D). This Ap5A concentration reduced [
3H]ADP
metabolism by 60–70% on mucosal and serosal surfaces (Fig.
6C).
The possibility remained that this inhibition reflected, at
least in part, interactions between Ap5A and ADP-dephospho-
rylating enzymes reported on these cells (4, 29–32). To address
this question, we took advantage of the substrate specificity
and ion requirements of ecto-AK (Fig. 4). The hydrolysis of 2
mM [3H]UDP was reduced from 0.73 nmolmin1cm2 to 0.59
nmolmin1cm2 by 0.5 mM Ap5A on the mucosal surface (Ta-
ble I). Since [3H]UDP is not a substrate of ecto-AK (Fig. 4C), the
difference between these two reaction rates would represent
inhibition of dephosphorylating enzymes by Ap5A (Table I,
reaction 8). Similar results were obtained when [3H]ADP me-
tabolism was assayed in Mg2-free KRB (data not shown),
which does not support ecto-AK activities (Fig. 4A). Reverse AK
activity, calculated from Ap5A-sensitive ADPase activity (Table
I, reaction 5) and corrected for nonspecific Ap5A interactions
(Table I, reaction 8), was not significantly different (Table I,
reaction 9) from values calculated by ATP production (Table I,
reaction 2). Altogether, these experiments clearly demonstrate
that ADP metabolism occurs mostly (60%) by transphospho-
rylation on human airway epithelial surfaces.
Impact of Ecto-AK on the Metabolism of ATP—We designed
time course experiments to investigate the impact of ecto-AK
on ATP and other receptor agonists (ADP and adenosine) gen-
erated during cell surface metabolism. Since dephosphorylat-
ing ectoenzymes hydrolyze ATP and UTP (for a review, see Ref.
51), whereas ecto-AK is specific for adenine nucleotides (for a
review, see Ref. 34) (Fig. 4, C and D), the phosphotransferase
activity would be responsible for any discrepancy between the
patterns of ATP and UTP metabolism through time. These
experiments were conducted with substrate concentrations (10
M) relevant to stimulated nucleotide release and P2 receptor
activation (for a review, see Ref. 52). Fig. 7, A and B, shows that
initial hydrolytic rates for [3H]UTP were lower than for
[3H]ATP with values of 7.9  1.2 nmolmin1cm2 and 12.1 
2.3 nmolmin1cm2, respectively (p  0.01). However,
whereas [3H]UTP and [3H]UDP were undetectable after 30 min
(Fig. 7A), [3H]ATP and [3H]ADP concentrations remained
above 1 M throughout the experiment (Fig. 7B). Uridine con-
centration rapidly plateaued at 5–6 M within 20 min, whereas
adenosine gradually reached 4 M by the end of the experiment.
The reversible transphosphorylating activity of ecto-AK on
adenine nucleotides could be responsible for the differences in
UTP and ATP metabolism. The initial faster rates of [3H]ATP
degradation and [3H]ADP accumulation could reflect the com-
bination of [3H]ATP dephosphorylation into [3H]ADP and phos-
phorylation of [3H]AMP into [3H]ADP. During the following 15
min, the reversible ecto-AK reaction competed with dephospho-
rylating enzymes to prolong the pools of [3H]ATP, [3H]ADP,
FIG. 6. Contribution of ecto-AK to ADP metabolism on human
bronchial epithelial cells. Epithelial cultures were incubated with
KRB (pH 7.4) containing bilateral 2 mM [3H]ADP (0.5 Ci), and buffer
samples collected over 60 min were analyzed by HPLC. A, concentration-
dependent inhibition of [3H]ATP production on mucosal (filled bars) and
serosal (open bars) surfaces by Ap5A. B, in the presence of 0.5 mM Ap5A,
the metabolic pattern of 0.1 mM ADP was similar to that of 0.1 mM UDP
(Fig. 4D). f, ADP; Œ, AMP; , adenosine; , inosine. C, ADPase and
ecto-AK activities detected on mucosal and serosal surfaces. Enzyme
activities measured without (filled bars, total ADPase) or with (open
bars, ADPase without ecto-AK) 0.5 mM Ap5A were 2–3-fold higher on
the mucosal surface (p  0.01). Complete inhibition of ecto-AK with 0.5
mM Ap5A reduced the rate of ADP hydrolysis by 70% on both surfaces
(*, p  0.01). Values represent  S.E. of 5–7 independent experiments.
TABLE I
Measurements of ecto-adenylate kinase activity at the surface of human bronchial epithelial cells
Values represent means ( S.E.) of six experiments.
Enzyme reaction Substrates (1 mM) Parameter Mucosal Serosal
nmol/min  cm2
1. AK forward [32P]ATP  AMP [32P]ADP production 1.19  0.14 0.34  0.09
2. AK reverse 2[3H]ADP [3H]ATP production 0.53  0.08 0.11  0.06
3. Total ADPase 2[3H]ADP 2[3H]ADP hydrolysis 0.92  0.10 0.46  0.07
4. ADPase-AK 2[3H]ADP  Ap5A 2[
3H]ADP hydrolysis 0.26  0.03 0.33  0.07
5. AK Reactions 3–4 0.66  0.05 0.13  0.03
6. Total UDPase 2[3H]UDP 2[3H]UDP hydrolysis 0.73  0.08 0.29  0.04
7. UDPase-DPEs 2[3H]UDP  Ap5A 2[
3H]UDP hydrolysis 0.59  0.12 0.27  0.03
8. DPEs[Ap5A]
a Reactions 5–6 0.14  0.02 0.02  0.01
9. AK corrected for DPEs[Ap5A] Reactions 5–7 0.52  0.17 0.11  0.03
a DPEs(Ap5A), Ap5A-sensitive non-AK dephosphorylating enzyme activities.
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and [3H]AMP. Adenine nucleotide concentrations eventually
decreased below the micromolar range, suggesting that phos-
phate groups were escaping the nucleotide entrapment cycle,
most likely through conversion of AMP into adenosine by the
high affinity ecto-5-nucleotidase activity (Km 	 14 M) we
described on these cells (30). Consequently, ecto-AK would
prolong P2 receptor agonist availability and delay A2B receptor
activation over a finite period of time following ATP release.
Lazarowski and Boucher (53) reported the presence of AMP
on the mucosal surface of human airway epithelial cultures. We
hypothesized that endogenous AMP concentrations would be
sufficient to support transphosphorylation events initiated by
the addition of 10 M [-32P]ATP. Fig. 8A shows HPLC traces
for KRB samples collected 0, 1, and 2 min after the addition of
[-32P]ATP to the mucosal surface. The reaction generated
[32P]inorganic phosphate and two peaks that co-migrated with
ADP and UTP standards. The rapid conversion of endogenous
AMP into [-32P]ADP (Fig. 8B) suggests that ecto-AK plays a
significant role in the availability of extracellular adenine nu-
cleotides supporting MCC in human airways. The production of
[-32P]UTP corroborated earlier reports of ecto-NDPK activity
on these cultures (32), whereby -phosphate was transferred
from [-32P]ATP to endogenous UDP.
Impact of Cystic Fibrosis on Human Airway Ecto-AK—The
airways of CF patients are characterized by severe inflamma-
tory responses to chronic bacterial infection, resulting from
defective MCC (for a review, see Ref. 41). We investigated the
long term effects of airway obstruction, chronic infection, and
inflammation on the activity of human airway ecto-AK. Pri-
mary cultures of bronchial epithelial cells from normal donors
and CF patients were assayed for forward and reverse ecto-AK
activities with 2 mM [3H]ADP and 1 mM [-32P]ATP  1 mM
AMP, respectively. Fig. 9A indicates that CF was associated
with 2-fold higher forward and reverse ecto-AK activities on
the mucosal surface (p  0.05). Interestingly, the disease had
no significant effect on serosal ecto-AK. Fig. 9B shows that
total ADPase activity was enhanced 2-fold by CF on the muco-
sal epithelial surface. Assays repeated in Mg2-free KRB indi-
cated that ecto-AK was mostly responsible for the impact of CF
on ADP metabolism (Fig. 9B). These experiments demon-
strated that ecto-AK activity is enhanced by CF on the mucosal
surface of human airway epithelia.
DISCUSSION
In the present study, we have demonstrated that extracellu-
lar adenine nucleotide concentrations on human airway epithe-
lial surfaces are regulated by a complex interplay between
dephosphorylating and transphosphorylating ectoenzymes. Ex-
tracellular ATP was rapidly dephosphorylated by the stepwise
reaction: ATP 3 ADP 3 AMP 3 adenosine, as generally re-
ported for mammalian cells (for a review, see Ref. 54). Exper-
iments conducted with ADP as the initial substrate produced
unexpected results that could not be revealed by standard
phosphate assays. The reaction exhibited dephosphorylating
activity by the production of AMP and adenosine, as well as
phosphorylating activity by the accumulation of ATP. The ob-
servation that Ap5A prevented ATP formation suggested that
an ecto-AK was responsible for the phosphorylation of ADP
(37). Indeed, experiments performed herein clearly showed
that human bronchial epithelial surfaces display both forward
(ATP  AMP3 ADP  ADP) and reverse (ADP  ADP3 ATP
 AMP) reactions characteristic of an AK activity (for a review,
see Ref. 34).
We first addressed the distribution of ecto-AK on human
airway epithelial surfaces. The primary bronchial cultures ex-
hibited the morphologic characteristics expressed in vivo (45)
with a layer of columnar ciliated and secretory cells covering
FIG. 7. Contribution of ecto-AK to UTP and ATP metabolism
on human bronchial epithelial cells. The mucosal surface was as-
sayed in KRB (pH 7.4) containing mucosal 0.01 mM [3H]UTP (0.5 Ci)
(A) or 0.01 mM [3H]ATP (0.5 Ci) (B). Mucosal buffer samples collected
over 20 min were analyzed by HPLC. , [3H]UTP and [3H]ATP; f,
[3H]UDP and [3H]ADP; Œ, [3H]UMP and [3H]AMP; , [3H]uridine and
[3H]adenosine; , inosine. The patterns represent mean results from
seven independent experiments (S.E.  10% of the mean).
FIG. 8. Detection of ecto-AK activity with endogenous nucleo-
tides on human bronchial epithelial surfaces. Assays were con-
ducted in KRB (pH 7.4) containing mucosal 0.01 mM [-32P]ATP (0.1
Ci). Buffer samples (10 l) collected over 10 min were analyzed by
HPLC. A, HPLC traces showing that ecto-AK converted endogenous
AMP into [-32P]ADP. Small amounts of [-32P]UTP were also identi-
fied by nucleotide standards, indicating ecto-NDPK activity. As shown
in B, [-32P]ADP accumulation reached a maximum within 2 min.
HPLC traces represent typical results (S.E.  10% of the mean), and
values (B) are mean  S.E. of four independent experiments.
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1–2 layers of basal-like cells. Both forward and reverse ecto-AK
reactions were bilaterally distributed with 4-fold higher activ-
ities on the mucosal than on the serosal surface. The mucosal
surface is comprised of the apical surface of the columnar cells
and a thin liquid layer, i.e. airway surface liquid. Time course
experiments indicated that more than 90% of the mucosal
ecto-AK activity remained associated to the epithelial surface.
Similar results were reported for human nasal epithelial cul-
tures, whereby released AK represented 20% of total ecto-AK
activity measured on the mucosal surface (40). Given the short
half-life of extracellular nucleotides within the airway surface
liquid (i.e. 0.2 mM UTP; t1⁄2 30 s (55)), these findings suggest
that human airway ecto-AK is likely to target extracellular
nucleotides released by the epithelium.
The kinetic properties of human airway ecto-AK at first
glance may not suggest a significant role in the modulation of
physiological nucleotide concentrations on airway surfaces.
Ecto-AK transphosphorylated ATP and ADP with Km values of
23 and 43 M, respectively. Although these values are lower
than for ecto-AK on rat brain synaptosomes (Km, ATP 	 460 M
(37)) and human endothelial cells (Km, ATP 	 135 M (38)),
ATP concentrations on airway epithelial surfaces, measured by
luciferin-luciferase assays in bulk solutions, are 100-fold
lower under both basal (1–10 nM) and stimulated (5–200 nM)
conditions (56, 57). It is important to consider, however, that
measurements of endogenously released ATP in large buffer
volumes may significantly underestimate near cell surface con-
centrations. A biosensor technique, using P2X2R-expressing
PC12 cells as probes, detected 13 M ATP at the surface of
osmotically challenged intestinal epithelial cells, as compared
with 5 nM by the “bulk fluid” luciferin-luciferase assay (57).
Single cell confocal bioluminescence luciferase assays (58) and
cell-attached luciferase assays (59) also measured ATP concen-
trations as high as 10–80 M in close vicinity to the site of
stimulated release. These studies suggest that ecto-AK may
influence physiological nucleotide concentrations on human
airway epithelial surfaces, particularly following an osmotic or
mechanical stimulation.
Most dephosphorylating and transphosphorylating ectoen-
zymes characterized on human airway epithelial surfaces ex-
hibit substrate affinities in the low micromolar range. Ecto-5-
nucleotidase hydrolyzed AMP into adenosine with a Km of 14
M (30), and ecto-nucleotide pyrophosphatase/phosphodiester-
ases (ATP 3 AMP  PPi) dephosphorylated ATP with a Km of
13 M (60). Nonspecific alkaline phosphatase displayed high
affinity (Km 	 36 M) and low affinity (Km 	 717 M) activities
toward AMP (30). Lazarowski et al. (32) demonstrated that an
ecto-NDPK influences endogenous concentrations of purine
and pyrimidine nucleotides (ATP  UDP u ADP  UTP) on
human nasal epithelial surfaces. When expressed in the hu-
man 1231N1 astrocytoma cell line, this enzyme presented a
higher substrate affinity for ADP (Km 	 17 M) than for ATP
(Km 	 93 M) (46). Collectively, these data suggest substantial
interactions between dephosphorylating and transphosphoryl-
ating reactions on human airway epithelial surfaces.
A key finding of this work is the demonstration that ecto-AK
competes with dephosphorylating enzymes to maintain adenine
nucleotides on human airway epithelial surfaces. The higher
affinity of human bronchial ecto-AK for ATP over ADP translated
into 3-fold higher rates for the forward (ATP  AMP3 ADP 
ADP) than the reverse (ADP  ADP 3 ATP  AMP) reaction.
This directionality could reduce the loss of phosphate groups
through AMP dephosphorylation. We explored this possibility by
taking advantage of the substrate specificity of AKs for adenine
nucleotides (Fig. 4) (for a review, see Ref. 34). Time course ex-
FIG. 9. Impact of CF on human bronchial ecto-AK. As shown in
A, CF enhanced ecto-AK activity on the mucosal surface but not on the
serosal surface. Epithelial cultures from normal donors or CF patients
were incubated with KRB (pH 7.4) containing 1 mM [-32P]ATP (0.1
Ci)  1 mM AMP (Forward Reaction) or 2 mM [3H]ADP (0.5 Ci;
Reverse Reaction). Buffer samples (10 l) collected over 60 min were
analyzed by HPLC for [-32P]ADP or [3H]ATP production. As shown in
B, the impact of CF on ADP metabolism was limited to ecto-AK. Assays
were conducted in KRB (pH 7.4) containing 2 mM [3H]ADP, without (0.5
Ci; total ADPase) or with (ADPase  AK) 0.5 mM Ap5A. Values
represent  S.E. of 5–7 independent experiments with epithelial cul-
tures from normal donors (filled bars) or CF patients (empty bars) (*,
p  0.05).
FIG. 10. Ecto-AK and adenine nucle-
otide-mediated MCC on human air-
way epithelial surfaces. Mechanical
stimulation induces bilateral ATP re-
lease, which is prolonged by the nucleo-
tide entrapment cycle of ecto-AK or
dephosphorylated into adenosine. Activa-
tion of bilateral P2Y2 (ATP), P2X4 (ATP
 ADP), and P2X5 (ATP  ADP) recep-
tors, and serosal P2Y1 receptors (ADP 
ATP), leads to cytosolic Ca2 mobilization
and stimulation of MCC-related cellular
functions:CBF,mucinsecretion,andCa2-
dependent Cl channels (ICA). Adenosine
maintains basal CBF and cystic fibrosis
transmembrane regulator (CFTR) con-
ductance by bilateral activation of A2B
receptors.
Ecto-Adenylate Kinase and Nucleotide-mediated MCC11262
periments on the metabolism of ATP and UTP indicated that
ecto-AK significantly extends the duration of micromolar adenine
nucleotides on epithelial surfaces while reducing adenosine pro-
duction (Fig. 7). The kinetic constant of ecto-AK for the forward
reaction is comparable with the affinity of ecto-5-nucleotidase for
AMP on these cultures (KmAMP 	 14 M (30)). Consequently,
ecto-AK could significantly interfere with the conversion of AMP
into adenosine by ecto-5-nucleotidase, delaying the transition
between P2 and P1 receptor-mediated signaling pathways on
airway epithelial surfaces.
Perhaps the most compelling evidence for the physiological
relevance of this nucleotide entrapment cycle was obtained
from assays conducted with endogenous nucleotides. Adenine
nucleotide and nucleoside concentrations measured on the mu-
cosal surface of human nasal epithelial cells by etheno derivat-
ization assays in bulk fluid were: ATP (10 nM), ADP (40 nM),
AMP (70 nM), and adenosine (200 nM) (53). Because AMP levels
are significantly higher than ATP under basal conditions, stim-
ulated ATP release would drive the forward ecto-AK reaction
(ATP  AMP3 ADP  ADP), thus minimizing nucleotide loss
through AMP dephosphorylation. The fact that [-32P]ADP
accumulated from endogenous AMP and an [-32P]ATP con-
centration (10 M; Fig. 8), mimicking stimulated release (57–
59), supports such a role for ecto-AK on human airway epi-
thelial surfaces. Furthermore, since ADP metabolism occurs
mostly through ecto-AK on these cells, this ADP pool could
constitute a significant source of extracellular ATP through
the reverse reaction (ADP  ADP 3 ATP  AMP). Conse-
quently, during a limited period following ATP release,
ecto-AK could efficiently compete with dephosphorylating ec-
toenzymes to prolong the availability of ATP and ADP for P2
receptor activation.
Based on the properties of ecto-AK, the dephosphorylating
ectoenzymes (4, 29–32), P2XRs and P2YRs on human airway
epithelial surfaces, we propose the following model for adenine
nucleotide-mediated MCC (Fig. 10). Immediately following lo-
cally stimulated ATP release, the nucleotide concentration is at
its highest, in a range that activates P2XRs (EC50 	 10 M; for
a review, see Refs. 62 and 63). P2XRs may desensitize rapidly,
i.e. within 30 s (16, 20), suggesting that a prolonged ATP level
may not be important for signaling. On the other hand, P2YRs
are activated by lower ATP concentrations (EC50 	 0.1–1 M;
for a review, see Ref. 21) and desensitize less rapidly. For
instance, Cl currents (61) and CBF (19) induced by 100 M
ATP on airway epithelial surfaces remained above 60% of max-
imal response for at least 15 min. Therefore, ecto-AK may have
a more pronounced effect on P2Y2R activation and P2Y2R-
linked effectors because ecto-AK may significantly prolong the
duration of ATP in the relevant concentration range (1–2 M;
Fig. 8B). As nucleotide concentrations decrease with time, the
high affinity dephosphorylating activities (Kms 	 5–17 M (31))
will eventually dominate over ecto-AK (Kms 	 23 M and 43
M), and basal MCC functions will be maintained through
adenosine receptor activation (19, 25–28).
In conclusion, we have demonstrated the co-existence of
ATP-consuming and ATP-generating pathways on human air-
way epithelial surfaces. The biochemical and kinetic properties
of ecto-AK suggest that the transphosphorylase activity could
participate in the propagation of MCC along airway epithelial
surfaces. Following stimulated ATP release, ecto-AK would
compete with dephosphorylating enzymes to maintain effective
nucleotide concentrations for P2Y and possibly P2X receptor
activation, resulting in enhanced Ca2-dependent Cl secre-
tion, CBF, and mucus secretion and, ultimately, acceleration of
MCC. Interestingly, we have shown that ecto-AK is up-regu-
lated in chronic obstructive airway diseases like CF. As extra-
cellular nucleotides are key regulators of MCC in CF (for a
review, see Ref. 1), up-regulation of AK activity may be an
adaptive response in these diseases.
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